Janssen Announces European Commission Approval of Imbruvica▼(ibrutinib) for Expanded Use in Two Indications

Posted in Biotech

August 13, 2019 • 2 min read

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the European Commission (EC) has approved variations to broaden the use of Imbruvica® (ibrutinib) in two indications. This includes the use of ibrutinib in combination with obinutuzumab in adult patients with previously untreated chronic lymphocytic leukaemia...

Novartis Addresses FDA Data Manipulation Inquiry

Posted in Biotech

August 07, 2019 • 2 min read

The FDA announced they were informed by AveXis, Inc., the gene therapy subsidiary of Novartis, that data was knowingly manipulated and inaccurate in their application for Zolgensma...

Highest-paid CEOs in healthcare in 2018

Posted in Biotech,

May 31, 2019 • 2 min read

The New York Times and Equilar published their 2018 ranking of highest-paid CEOs and thirty-two healthcare CEO's made the list. The list was built by referencing 200 CEOs from public companies with revenue of at least $1 billion....